Oncimmune and Roche expand biomarker discovery project

27 July 2020

Swiss giant Roche (ROG: SIX) has exercised an option to increase the scope and value of a research project with UK-based immunodiagnostics firm Oncimmune Holdings (AIM: ONC).

The decision builds on a contract, agreed in May 2020, to undertake immune profiling with the goal of understanding individual patient responses to immunotherapy.

The project is built around Oncimmune's proprietary SeroTag biomarker discovery platform, which the firm has been using to profile patient samples collected by Roche during their cancer immunotherapy trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK